Genentech DNA
-
Timing Is Everything Vs. Seductive Hype
… Digest ): In the mid-1980s discoveries in biotechnology were revealed and investors piled-into many new companies like Genentech and Amgen. But the technology was yet to produce profits for many years to come. Mutual fund companies devoted some funds …
-
New Morningstar Analyst Report for Rigel Pharmaceuticals, Inc.
… 1996, he was CEO of Tularik, a biotechnology firm that was later bought by Amgen. Before Tularik, he spent 10 years at Genentech . We are encouraged to see strong insider ownership of more than 10% of the firm, which we believe is sufficient to align …
-
New Morningstar Analyst Report - Exelixis, Inc.
… many chances to get an oncology drug approved.Exelixis' partnerships with larger players such as Glaxo, Bristol, and Genentech help stabilize drug development and lend credibility to the firm's potential.Cabozantinib has shown activity in a variety …
-
Multiple Antigen Targeting Could Indicate Big Potential For Immunotherapy Drugs
… substantial. The current king of multiple indications is Genentech 's Avastin (bevacizumab), a single therapy that is used ..... trastuzumab), an anti-HER2/neu antibody also from Genentech , is approved for both breast and gastric cancers and has …
-
PBE PowerShares Dynamic Biotech & Genome ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… the biotech industry, providing another potential catalyst for investors. The headline merger was Roche's acquisition of Genentech , but other recent deals have occurred as well, including Sanofi-Aventis' SNY acquisition of Genzyme. With a blitz of …
-
BBH Market Vectors Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… the biotech industry, providing another potential catalyst for investors. The headline merger was Roche's acquisition of Genentech , but other recent deals have occurred as well, including Sanofi-Aventis' SNY acquisition of Genzyme. With a blitz of …
-
IBB iShares Nasdaq Biotechnology ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… the biotech industry, providing another potential catalyst for investors. The headline merger was Roche's acquisition of Genentech , but other recent deals have occurred as well, including Sanofi-Aventis' SNY acquisition of Genzyme. With a blitz of …
-
XBI SPDR S&P Biotech ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… the biotech industry, providing another potential catalyst for investors. The headline merger was Roche's acquisition of Genentech , but other recent deals have occurred as well, including Sanofi-Aventis' SNY acquisition of Genzyme. With a blitz of …
-
FBT First Trust NYSE Arca Biotech Index ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… biotech industry, providing another potential catalyst for investors. The headline merger has been Roche's acquisition of Genentech , but other recent deals have occurred as well, including Sanofi-Aventis' SNY purchase of Genzyme. With a blitz of generic …
-
IHE iShares Dow Jones US Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… innovative research and development programs. Recent mergers and acquisitions in the space have included Roche's acquisition of Genentech , Teva Pharmaceutical Industries' TEVA acquisition of German generic drugmaker Ratiopharm Group International, Sanofi …